Close menu




BAYER AG NA

Photo credits: pixabay.com

Commented by André Will-Laudien on June 21st, 2024 | 07:00 CEST

Biotech: What counts is selection! Bayer, Vidac Pharma, Formycon, and Evotec in focus

  • Biotechnology
  • Pharma
  • Biotech

The biotech sector has so far been unable to keep pace with the high-tech-heavy NASDAQ. However, there are now signals from the central banks that a turnaround in interest rates is imminent. This is because, on the one hand, the US economy is weakening, and on the other hand, inflationary pressure appears to be easing. With lower interest rates, life science companies can refinance themselves more cheaply. Due to the different dynamics, it is now important to fish out the pearls. We select attractive entry levels.

Read

Commented by Fabian Lorenz on June 18th, 2024 | 06:30 CEST

Price jump at TUI! Bayer share price slumps! Globex Mining makes millions!

  • Mining
  • Gold
  • Commodities
  • Pharma
  • Travel

TUI shares were among the day's winners on the German stock market yesterday. The tourism group benefited not only from positive analyst comments but also from the FTI bankruptcy. Can the share now end its months-long sideways movement? There are also good reasons for higher prices at Globex Mining. The mining incubator recently received CAD 3 million from the gold group Agnico Eagle - and that is not the end of the story. The latest analyst comments on Bayer shares are not very promising. Yesterday's DAX share price reaction was correspondingly negative. However, the management was optimistic.

Read

Commented by Armin Schulz on June 10th, 2024 | 07:15 CEST

Evotec, Vidac Pharma, Bayer - Biotech and Pharma: Opportunities for investors

  • Biotechnology
  • Pharma

In the constantly evolving pharmaceutical and biotechnology industry landscape, innovative strength and strategic orientation play a decisive role in success. Both established groups and young, up-and-coming companies are competing for market share and scientific breakthroughs. In this context, it is worth taking a closer look at Vidac Pharma, Bayer and Evotec. These companies are pursuing different approaches and strategies to achieve their respective goals. How do they manage to hold their own in a highly dynamic market environment, and what prospects are emerging for the future?

Read

Commented by André Will-Laudien on June 6th, 2024 | 07:00 CEST

Rally start for biotech! Evotec, Bayer, Defence Therapeutics, CureVac and BioNTech in pole position

  • Biotechnology
  • Pharma

Sell in May and go Away! Far from it, as the stock markets continue to rise steadily in June. After a disappointing start to the year, the biotech sector is now also showing signs of recovery. Bayer and Evotec seem to have found their footing with improved outlooks. BioNTech, CureVac and Defence Therapeutics are providing promising data on various cancer vaccines. Whoever opens the door here can save millions of lives. And investors stand to make a fortune if one of the vaccines hits the mark. We analyze the opportunities and risks.

Read

Commented by Armin Schulz on June 5th, 2024 | 07:00 CEST

Bayer, Saturn Oil + Gas, TUI - Big price gains beckon here

  • Mining
  • Oil
  • Pharma
  • Travel

The shares of Bayer, Saturn Oil & Gas and TUI have the potential to rise in the near future. At Bayer, the negative effects of the challenging year 2023 appear to have been priced in. Saturn Oil & Gas impresses with a strong cash flow and is traded as a future dividend share. Analysts see potential of over 100% here. TUI's balance sheet problems have largely been resolved, and the forecasts for 2024 and the summer season promise record bookings, which could give the share an additional boost - reason enough for us to take a closer look at the three companies.

Read

Commented by André Will-Laudien on May 30th, 2024 | 07:00 CEST

Already up 180% in 2024 - Who offers more? BioNTech, Bayer, Cardiol Therapeutics, or Evotec?

  • Biotechnology
  • Pharma

For investors in the biotech sector, 2024 has been a very rocky year. Everyone is waiting for the big breakthrough, which has yet to appear. In a sector where there is no longer a pandemic and cancer research is still stuck, selection has become very important. Complicating matters is the investor-unfriendly capital market interest rate, with hopes resting on support from central banks quarter by quarter. This makes it all the more important to identify and follow the most innovative business models. BioNTech does not currently have a blockbuster but still has a good EUR 17 billion in its coffers. Pharmaceutical giant Bayer has seen its share price drop to a fifth of its 2019 value, and Evotec also resembles a disaster. Cardiol Therapeutics has performed well so far - what is next for them?

Read

Commented by Armin Schulz on May 23rd, 2024 | 08:30 CEST

E.ON, MGI - Media and Games Invest, Bayer - Through transformation into a golden future

  • renewableenergies
  • Pharma
  • Innovations
  • Digitization
  • Media

Sometimes, companies are forced to overhaul their business areas if they wish to survive. A transformation is then unavoidable, and hopefully, the companies emerge stronger in the end. However, there is also the possibility that management will recognize the signs of the times early on and adapt their business models. From traditional companies that are starting a second life through digital innovation to young start-ups that are becoming market leaders through strategic realignments, companies are constantly facing challenges. Their path to a golden future is characterized by visionary decisions, agile adjustments and an unwavering will to improve continuously. We have selected three candidates that are currently undergoing a transformation.

Read

Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST

Bayer, Defence Therapeutics, Novavax - Major events

  • Biotechnology
  • Pharma

The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.

Read

Commented by Fabian Lorenz on May 9th, 2024 | 08:00 CEST

Stocks facing revaluation! Nel ASA, Bayer, Power Nickel with potential

  • Mining
  • Gold
  • Silver
  • Nickel
  • Pharma
  • renewableenergies

Relief for Bayer. In the US, the Company has won a victory in the dispute over compensation for illnesses caused by the chemical PCB. Is it groundbreaking and the start of a revaluation of the share? A revaluation already seems to be underway at Power Nickel. Following sensational drilling results, the share price soared. Surprisingly, gold, silver and copper were also found. Against this backdrop, the share appears to be favorably valued. Does this also apply to Nel? After all, the share price has risen by around 20% in just a few weeks. Is there new hope for the hydrogen pioneer? Or are today's figures from industry peer Plug Power threatening a new sell-off?

Read

Commented by André Will-Laudien on May 9th, 2024 | 07:00 CEST

Biotech and pharma stocks finally follow suit! Novo Nordisk, Bayer, BioNTech, Vidac Pharma and Evotec on the buy list

  • Biotechnology
  • Pharma

Things looked very different at the beginning of the year. After a brilliant rally in the Nasdaq Biotech Index at the end of last year, investors thought the upswing could continue in 2024. So far, this hope has not been confirmed. The main focus for the industry is the refinancing conditions. These have gradually deteriorated, as stubborn inflation is keeping central bank interest rates high. And judging by the wording of central bankers, the next interest rate cut does not seem to be penciled in yet. However, if it happens in the summer, things will likely move quickly for the life sciences sector. Then a quick sector rotation is the order of the day! Here is our buy list for the upcoming event.

Read